BIOMAT Database Logo BIOMAT Database Logo

[Evaluation of the combination of chemotherapy with etoposide, adriamycin and cisplatin (EAP) in advanced or recurrent gastric cancer]. 1993

N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
1st Dept. of Surgery, Shiga University of Medical Science.

EAP therapy was performed on 30 cases of advanced or recurrent gastric cancer between September 1987 and July 1991. The clinical responses of 15 trial patients were evaluated. The overall response rate was 40.0% (CR, one case; PR 5 cases). The results were thus not as favorable as that reported by Preusser et al. On the contrary, with such a poor response rate, this treatment did not lead to a prolonged life span (mean survival time; 5.6 months, median survival time; 4 months). Side effects, such as myelosuppression, appetite loss, nausea, vomiting, liver dysfunction, renal dysfunction, and alopecia, were also observed. Myelosuppression was a dose-limiting factor. The rhG-CSF proved in 4 cases to be a clinically useful tool against the neutropenia induced by this treatment. It may be concluded that EAP should be given to the following selected patients: (1) those whose condition is not so far advanced: (2) those who have not received many other forms of treatment; and (3) those in excellent general physical condition.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
[Advanced and recurrent gastric carcinoma: combination chemotherapy with etoposide (E), adriamycin (A), cisplatin (P) = EAP].
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
[Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
July 1991, Hinyokika kiyo. Acta urologica Japonica,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: association with severe toxicity.
April 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: association with severe toxicity.
April 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
October 1994, Japanese journal of clinical oncology,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
[Evaluation of EAP (etoposide, adriamycin, cisplatin) for highly advanced gastric cancer in a neoadjuvant setting].
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
[Combination therapy with etoposide, adriamycin and cisplatin in advanced primary and recurrent gastric cancer].
December 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
[Combination chemotherapy with etoposide, ADM, and CDDP (EAP) for advanced gastric cancer].
November 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer.
October 1990, American journal of clinical oncology,
N Terata, and H Sano, and H Ishibashi, and T Tani, and K Hanasawa, and Y Endo, and Y Kurumi, and J Shibata, and M Kodama, and K Tsuji
Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer.
June 1994, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!